Paper40565145
Anti-lymphoma Activity of Acyclic Terpenoids and Its Structure-Activity Relationship: In Vivo, In Vitro, and In Silico Studies.
Calzada F and 5 others. Int J Mol Sci, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Anti-lymphoma Activity of Acyclic Terpenoids and Its Structure-Activity Relationship: In Vivo, In Vitro, and In Silico Studies. Papers, record 40565145. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40565145
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anti-lymphoma Activity of Acyclic Terpenoids and Its Structure-Activity Relationship: In Vivo, In Vitro, and In Silico Studies.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Terpenes | Major topic |
| Lymphoma | Major topic |
| Antineoplastic Agents | Major topic |
| Antineoplastic Agents, Phytogenic | Major topic |
| Animals | |
| Molecular Docking Simulation | |
| Mice | |
| Structure-Activity Relationship | |
| Male | |
| Cell Line, Tumor | |
| Mice, Inbred BALB C | |
| Humans | |
| Computer Simulation | |
| Cell Proliferation |
Source PubMed
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22294375 | Overview on the Rule of Five. | Curr Protoc Pharmacol | 2010 | https://conductscience.org/library/papers/22294375 | PubMed |
| 2 | 27562463 | The interplay between cell signalling and the mevalonate pathway in cancer. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/27562463 | PubMed |
| 3 | 8882960 | Analysis of the colonization of unirradiated and irradiated SCID mice by human lymphoma and non-malignant lymphoid cells. | Leuk Lymphoma | 1996 | https://conductscience.org/library/papers/8882960 | PubMed |
| 4 | 38647086 | ProTox 3.0: a webserver for the prediction of toxicity of chemicals. | Nucleic Acids Res | 2024 | https://conductscience.org/library/papers/38647086 | PubMed |
| 5 | 33893803 | ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. | Nucleic Acids Res | 2021 | https://conductscience.org/library/papers/33893803 | PubMed |
| 6 | 38731446 | In Vivo, In Vitro and In Silico Anticancer Activity of Ilama Leaves: An Edible and Medicinal Plant in Mexico. | Molecules | 2024 | https://conductscience.org/library/papers/38731446 | PubMed |
| 7 | 38523032 | BCL-2 inhibition in haematological malignancies: Clinical application and complications. | Blood Rev | 2024 | https://conductscience.org/library/papers/38523032 | PubMed |
| 8 | 31346132 | Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. | Oncologist | 2019 | https://conductscience.org/library/papers/31346132 | PubMed |
| 9 | 34675185 | Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. | Cell Death Dis | 2021 | https://conductscience.org/library/papers/34675185 | PubMed |
| 10 | 33358111 | Targeting the Mevalonate Pathway in Cancer. | Trends Cancer | 2021 | https://conductscience.org/library/papers/33358111 | PubMed |
| 11 | 32888407 | Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. | Lancet | 2020 | https://conductscience.org/library/papers/32888407 | PubMed |
| 12 | 28362175 | Synergistic Impact of d-δ-Tocotrienol and Geranylgeraniol on the Growth and HMG CoA Reductase of Human DU145 Prostate Carcinoma Cells. | Nutr Cancer | 2017 | https://conductscience.org/library/papers/28362175 | PubMed |
| 13 | 23291630 | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. | Nat Med | 2013 | https://conductscience.org/library/papers/23291630 | PubMed |
| 14 | 35267408 | Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35267408 | PubMed |
| 15 | 30135071 | Non-Hodgkin lymphoma. | BMJ | 2018 | https://conductscience.org/library/papers/30135071 | PubMed |
| 16 | 38812137 | [Study on mechanism of inhibiting proliferation of head and neck cancer cells by citral, active ingredient of lemon essential oil]. | Zhongguo Zhong Yao Za Zhi | 2024 | https://conductscience.org/library/papers/38812137 | PubMed |
| 17 | 26576807 | Open three-stage transthoracic oesophagectomy versus minimally invasive thoraco-laparoscopic oesophagectomy for oesophageal cancer: protocol for a multicentre prospective, open and parallel, randomised controlled trial. | BMJ Open | 2015 | https://conductscience.org/library/papers/26576807 | PubMed |
| 18 | 19399780 | AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. | J Comput Chem | 2009 | https://conductscience.org/library/papers/19399780 | PubMed |
| 19 | 18219762 | Terpenes: substances useful in human healthcare. | Arch Immunol Ther Exp (Warsz) | 2007 | https://conductscience.org/library/papers/18219762 | PubMed |
| 20 | 39036553 | Etiology of non-Hodgkin lymphoma: A review from epidemiologic studies. | J Natl Cancer Cent | 2022 | https://conductscience.org/library/papers/39036553 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42354121 | A Comprehensive Review of Bioactive Constituents, Health-Promoting Effects, Processing Technologies, and Industrial Applications of Sparassis crispa Sensu Lato. | Foods | 2026 | https://conductscience.org/library/papers/42354121 | PubMed |
| 42255243 | A systematic evaluation of double-expressor lymphoma: prognostic impact, determinants of outcome, and comparative efficacy and safety of novel therapies. | Front Oncol | 2026 | https://conductscience.org/library/papers/42255243 | PubMed |
| 42196355 | Essential Oils as a Source of Anticancer Molecules: Critical Assessment of Current Evidence and Methodological Limitations-A Systematic Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196355 | PubMed |
| 41011134 | Expanding the Knowledge of the Molecular Effects and Therapeutic Potential of Incomptine A for the Treatment of Non-Hodgkin Lymphoma: In Vivo and Bioinformatics Studies, Part III. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41011134 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| HMGCR | 3156 | PubTator's text mining | https://conductscience.org/library/genes/3156 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40565145
GET https://conductscience.org/api/papers/v1/40565145/references?page=2